Morphine enhances hepatitis C virus (HCV) replicon expression

Am J Pathol. 2003 Sep;163(3):1167-75. doi: 10.1016/S0002-9440(10)63476-1.

Abstract

Little information is available regarding whether substance abuse enhances hepatitis C virus (HCV) replication and promotes HCV disease progression. We investigated whether morphine alters HCV mRNA expression in HCV replicon-containing liver cells. Morphine significantly increased HCV mRNA expression, an effect which could be abolished by either of the opioid receptor antagonists, naltrexone or beta-funaltrexamine. Investigation of the mechanism responsible for this enhancement of HCV replicon expression demonstrated that morphine activated NF-kappaB promoter and that caffeic acid phenethyl ester, a specific inhibitor of the activation of NF-kappaB, blocked morphine-activated HCV RNA expression. In addition, morphine compromised the anti-HCV effect of interferon alpha (IFN-alpha). Our in vitro data indicate that morphine may play an important role as a positive regulator of HCV replication in human hepatic cells and may compromise IFN-alpha therapy.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Antiviral Agents / antagonists & inhibitors
  • Antiviral Agents / pharmacology
  • Enzyme Activation / drug effects
  • Gene Expression* / drug effects*
  • Hepacivirus / genetics*
  • Humans
  • Interferon-alpha / antagonists & inhibitors
  • Interferon-alpha / pharmacology
  • Morphine / pharmacology*
  • NF-kappa B / metabolism
  • Naltrexone / analogs & derivatives*
  • Naltrexone / pharmacology
  • Narcotic Antagonists / pharmacology
  • RNA, Messenger / metabolism
  • Receptors, Opioid, mu / antagonists & inhibitors
  • Receptors, Opioid, mu / metabolism
  • Replicon*
  • Tumor Cells, Cultured

Substances

  • Antiviral Agents
  • Interferon-alpha
  • NF-kappa B
  • Narcotic Antagonists
  • RNA, Messenger
  • Receptors, Opioid, mu
  • Naltrexone
  • beta-funaltrexamine
  • Morphine